Drug intelligence / Profile preview

sesiclenegene cosaparvovec

Development stage
Phase 2
Lead developer
The Abigail Wexner Research Institute
Modality
AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration
Intrathecal, Intravenous
01

Overview

Sesiclenegene cosaparvovec is an investigational AAV-based gene therapy designed for the treatment of neuronal ceroid lipofuscinosis type 6 (CLN6), a form of Batten disease. This therapy uses an adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the CLN6 gene to patient cells, aiming to restore or modulate the function of the defective CLN6 transmembrane endoplasmic reticulum protein. The mechanism involves gene transfer and modulation of CLN6 protein activity. Sesiclenegene cosaparvovec has received PRIME designation in the EU and is currently in Phase 2 clinical development for neuronal ceroid-lipofuscinoses.

Other names
CLN6 gene therapyCLN-6 gene therapyCLN 6 gene therapy
02

Targets

Gal (Terminal N-linked galactose)CLN6 (Ceroid-lipofuscinosis, neuronal 8 transmembrane ER and ERGIC protein)

Beyond the preview

Go deeper on sesiclenegene cosaparvovec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sesiclenegene cosaparvovec.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call